Core Viewpoint - The company reported a decline in revenue and net profit for the six months ending June 30, 2025, primarily due to macroeconomic challenges and intensified drug procurement policies [1] Financial Performance - The company's operating revenue decreased by 8.18% year-on-year to RMB 2.155 billion [1] - Net profit attributable to shareholders was RMB 21.739 million, a year-on-year decrease of 18.72% [1] - Basic and diluted earnings per share were RMB 0.2013 [1] Market Challenges - The slowdown in macroeconomic growth has put pressure on both upstream and downstream industry conditions, leading to a 20.52% year-on-year decline in revenue for the first quarter of 2025 [1] - The deepening drug procurement policy has resulted in a decrease in terminal prices for certain drugs, causing a contraction in the volume of some drug businesses [1] Recovery Strategy - In response to market challenges, the company quickly adjusted its operational strategy, resulting in a recovery in main business revenue, which grew by 6.48% year-on-year in the second quarter of 2025 [1]
创美药业(02289.HK)中期归母净利2173.9万元 同比减少18.72%